Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 148Biopsy 117pembrolizumab 91Carboplatin 85Cisplatin 77Nivolumab 71Cyclophosphamide 69Paclitaxel 64Gemcitabine 52Radiotherapy 48Bevacizumab 44durvalumab 41Dexamethasone 37Fluorouracil 35Doxorubicin 35venetoclax 34Pemetrexed 33Capecitabine 33olaparib 32Rituximab 31Oxaliplatin 31Injections 31atezolizumab 30Etoposide 29fludarabine 28Radiation 28Prednisone 28Lenalidomide 27Docetaxel 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × methoxyamine × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡